Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Cenix, CellCentric to develop oncology therapeutics
April 2008
SHARING OPTIONS:

DRESDEN, GermanyŚCenix Bio-Science GmbH, a leading specialist in advanced RNAi-based research services, has signed an agreement to support CellCentric Ltd., a biotechnology company unlocking epigenetic control mechanisms, through cell-based validation of novel therapeutic drug targets for oncology.

Cenix will combine high-throughput applications of RNAi-based gene silencing with high-content phenotypic analyses in cultured human cells. The initial project will focus on the in vitro validation of several candidate drug targets chosen by CellCentric to offer high therapeutic anti-cancer potential.

CellCentric is based in Cambridge, England.
 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
478 Bay Street, Suite A213
Midland, Ontario, Canada L4R 1K9
Ph: 888-781-0328 |  Fax: 705-528-0270
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.